Company Valuation: BioXcel Therapeutics

Data adjusted to current consolidation scope
Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 263.5 1,126 568.8 601.9 86.35 8.189 8.189 -
Change - 327.27% -49.47% 5.82% -85.65% -90.52% 0% -
Enterprise Value (EV) 1 231.1 912.7 335.9 501.3 122.2 104.4 110.3 44.66
Change - 294.89% -63.2% 49.24% -75.63% -14.52% 5.63% -59.51%
P/E ratio -7.23x -12.2x -5.02x -3.63x -0.48x -0.09x -0.14x -0.2x
PBR 8.85x 5.46x 2.57x 7.88x -1.52x -0.07x -0.15x -0.23x
PEG - -0.1x -0.73x -0.1x -0.12x 0x 0x 0x
Capitalization / Revenue - - - 1,605x 62.6x 2.88x 1.48x 0.69x
EV / Revenue - - - 1,337x 88.5x 36.7x 20x 3.75x
EV / EBITDA -6.91x -11.1x -3.15x -3.15x -0.71x -1.39x -1.46x -0.67x
EV / EBIT -6.88x -11.1x -3.14x -3.14x -0.71x -1.41x -1.62x -0.66x
EV / FCF -8.21x -13.7x -4.07x -3.7x -0.79x -1.32x -2.3x -0.59x
FCF Yield -12.2% -7.3% -24.6% -27% -127% -75.7% -43.5% -168%
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -32.32 -60.64 -64.8 -94.72 -98.4 -28.78 -19.43 -13.13
Distribution rate - - - - - - - -
Net sales 1 - - - 0.375 1.38 2.844 5.516 11.91
EBITDA 1 -33.44 -82.11 -106.6 -159.3 -171.4 -74.9 -75.4 -66.95
EBIT 1 -33.6 -82.3 -106.9 -159.6 -171.8 -73.94 -68.24 -67.32
Net income 1 -32.97 -82.17 -106.9 -165.8 -179.1 -64.49 -67.58 -76.15
Net Debt 1 -32.36 -213.1 -233 -100.7 35.82 96.24 102.1 36.47
Reference price 2 233.760 739.200 325.280 343.680 47.200 2.640 2.640 2.640
Nbr of stocks (in thousands) 1,127 1,523 1,749 1,751 1,830 3,102 3,102 -
Announcement Date 3/9/20 3/11/21 3/10/22 3/9/23 3/12/24 - - -
1USD in Million2USD
Estimates

P/E ratio, Detailed evolution

Year-on-year evolution of the PER

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

Year-on-year evolution of the Yield

  1. Stock Market
  2. Equities
  3. BTAI Stock
  4. Valuation BioXcel Therapeutics